SEC Form 4 · accession 0001104659-15-066536
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald J Hayden Jr.
Director
Period of report
Sep 21, 2015
Accepted (ET)
Sep 22, 2015 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 21, 2015 | M | 16,130 | $3.45 | A | 16,130 | D | |
| Common Stock | Sep 21, 2015 | S | 16,130 | $17.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.45 | Sep 21, 2015 | M | 16,130 | D | — | Mar 28, 2016 | Common Stock | 16,130 | 18,065 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2015.
- F2The option vested over three years of service following March 29, 2006, with 50% vesting upon completion of one year of service and in two equal annual installments thereafter.